TACSTD2 and lung carcinoma: The co-expression of EGFR and MUC1 was higher in tumor cells than EGFR combined with targets under active drug development for lung cancer such as MET, HER3 (ERBB3) or Trop2 (TACSTD2) (Figure 2), suggesting the potential safety advantage of developing therapies targeting EGFR and MUC1.